공지가 닫혀있습니다 l 열기
모바일 (밤모드 이용시)
 
카테고리
Intellia CEO on Crispr gene-editing treatment, secondary offering Intellia CEO on Crispr gene-editing treatment, secondary offering
Intellia shares jump on positive gene-editing data Intellia shares jump on positive gene-editing data
Intellia has a special request from FDA for their NTLA-2002. Must know this if you hold NTLA. Intellia has a special request from FDA for their NTLA-2002. Must know this if you hold NTLA.
Intellia Stock vs CRISPR Stock: The Winner Is Intellia Stock vs CRISPR Stock: The Winner Is
INTELLIA THERAPEUTICS INC BIG SWING | NTLA STOCK INTELLIA THERAPEUTICS INC BIG SWING | NTLA STOCK
Revolutionary CRISPR Therapy Tool | KEY MILESTONE Analysis on  Intellia Therapeutics (NTLA) stock Revolutionary CRISPR Therapy Tool | KEY MILESTONE Analysis on Intellia Therapeutics (NTLA) stock
Intellia is the leading CRISPR company Intellia is the leading CRISPR company
Revolutionary CRISPR Therapy Tool | Martin Shkreli Analyses Intellia Therapeutics (NTLA) stock Revolutionary CRISPR Therapy Tool | Martin Shkreli Analyses Intellia Therapeutics (NTLA) stock
Intellia Therapeutics Overview Intellia Therapeutics Overview
Intellia Therapeutics: MASSIVE Opportunity in CRISPR -  $NTLA Full Analysis Intellia Therapeutics: MASSIVE Opportunity in CRISPR - $NTLA Full Analysis
Intellia, Regeneron complete first systemic delivery of CRISPR in body Intellia, Regeneron complete first systemic delivery of CRISPR in body
CSHL Keynote, Dr. David Lebwohl, Intellia Therapeutics CSHL Keynote, Dr. David Lebwohl, Intellia Therapeutics
Gene Editing Updates | CRISPR, Intellia, and Beam Gene Editing Updates | CRISPR, Intellia, and Beam
Intellia: NTLA steady performance, well funded, no immediate catalysts - Earnings review, Intellia: NTLA steady performance, well funded, no immediate catalysts - Earnings review,
Intellia Therapeutics, Inc  NTLA Stock Intellia Therapeutics, Inc NTLA Stock
연예 인기글 l 안내
필터
1 ~ 10위
1 ~ 10위